Does RaDaR ST MRD Data at ESMO 2025 Shift the Bull Case for NeoGenomics (NEO)?

• NeoGenomics, Inc. recently presented data on its RaDaR ST molecular residual disease (MRD) assay, including results from interventional therapy trials, at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
• This announcement underscores NeoGenomics' push into precision oncology by leveraging personalized ctDNA panels to support real-time insights for pharmaceutical partners in drug development.
• We'll examine how showcasing the RaDaR ST MRD assay to pharma partners at ESMO could influence NeoGenomics' investment narrative.

We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

NeoGenomics Investment Narrative Recap

Owning shares of NeoGenomics means believing in the ongoing evolution of precision oncology, especially its ability to gain pharmaceutical partnerships and drive adoption of advanced testing like the RaDaR ST MRD assay. While this recent showcase at ESMO puts NeoGenomics' innovation in the spotlight, it may only modestly affect short-term catalysts such as new product launches; the most pressing risk remains ongoing revenue volatility tied to unpredictable pharma and biotech demand.

The recent commercial rollout of NEO PanTracer™ LBx stands out, coinciding directly with increased attention on liquid biopsy and MRD categories. Showcasing RaDaR ST at ESMO, soon after launching new blood-based tests for therapy selection, reinforces how NeoGenomics is pushing to expand its relevance in oncology testing and tap into growth areas that could offset the unpredictability of pharma sector revenues.

However, investors should also be aware that, in contrast, the revenue volatility from weaker or delayed pharma and biotech demand could ...

Read the full narrative on NeoGenomics (it's free!)

NeoGenomics' outlook forecasts $893.1 million in revenue and $48.1 million in earnings by 2028. This scenario assumes 9.0% annual revenue growth and a $152.1 million improvement in earnings from the current -$104.0 million.

Uncover how NeoGenomics' forecasts yield a $10.44 fair value, in line with its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community set fair value for NeoGenomics between US$10.20 and US$19.00 per share. Despite this range of opinions, risks from unpredictable pharma demand remain significant and could materially impact the company's future performance, so explore all perspectives before making assumptions.

Explore 3 other fair value estimates on NeoGenomics - why the stock might be worth as much as 82% more than the current price!

Build Your Own NeoGenomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NeoGenomics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com